Synthesis and characterization of novel 1,2,4-triazine derivatives with antiproliferative activity

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 5, 2010, Pages 1816-1821

  Krauth, Fabian ^a   Dahse, Hans Martin ^b   Rüttinger, Hans Hermann ^a   Frohberg, Petra ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

Author keywords

1,2,4 triazin 5 ones; Imatinib; K 562; Leukemia; log P; Rule of five; Serum albumin binding; Small molecules

Indexed keywords

1,2,4 TRIAZINE DERIVATIVE; 2,3,4,5 TETRAHYDRO 4 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL) 6 (MORPHOLIN 4 YL) 1,2,4 TRIAZIN 5 ONE; 2,3,4,5 TETRAHYDRO 4 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL) 6 (PIPERIDIN 1 YL) 1,2,4 TRIAZIN 5 ONE; 2,3,4,5 TETRAHYDRO 4 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL) 6 (PYRROLIDIN 1 YL) 1,2,4 TRIAZIN 5 ONE; 2,3,4,5 TETRAHYDRO 4 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL) 6 DIMETHYLAMINO 1,2,4 TRIAZIN 5 ONE; 2,3,4,5 TETRAHYDRO 4 (2 CHLOROPHENYL) 2 PHENYL 6 (MORPHOLIN 4 YL) 1,2,4 TRIAZIN 5 ONE; 2,3,4,5 TETRAHYDRO 4 (2 CHLOROPHENYL) 2 PHENYL 6 (PYRROLIDIN 1 YL) 1,2,4 TRIAZIN 5 ONE; 2,3,4,5 TETRAHYDRO 4 (2 CHLOROPHENYL) 6 DIMETHYLAMINO 2 PHENYL 1,2,4 TRIAZIN 5 ONE; DOXORUBICIN; IMATINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE; HELA CELLS; HUMANS; K562 CELLS; PROTEIN BINDING; PYRROLIDINES; SERUM ALBUMIN; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 77249091169     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.01.053     Document Type: Article

References (32)

1. Bhatia P.A., Brooks C.D.W., Basha A., Ratajczyk J.D., and Gunn B.P. J. Med. Chem. 39 (1996) 3938
2. Kim K.H., Martin Y.C., and Brooks C.D.W. Quant. Struct.-Act. Relat. 15 (1996) 491
3. Sztanke K., Pasternak K., Rajtar B., Sztanke M., Majek M., and Polz-Dacewicz M. Bioorg. Med. Chem. 15 (2007) 5480
4. Abdel-Rahman R.M. Pharmazie 56 (2001) 195
5. Pontillo J., Guo Z., Wu D., Struthers R.S., and Chen C. Bioorg. Med. Chem. Lett. 15 (2005) 4363
6. Sztanke K., Pasternak K., Sztanke M., Kandefer-Szerszen M., Koziol A.E., and Dybala I. Bioorg. Med. Chem. Lett. 19 (2009) 5095
7. Dallloul H.M., El-Hossain A.R.M., Shorafa H.Z., and El-Shorafa A.Z. ARKIVOC (2008) 207
8. Sztanke K., Pasternak K., Rzymowska J., Sztanke M., and Kandefer-Szerszen M. Eur. J. Med. Chem. 43 (2008) 1085
9. Hunt J.T., Mitt T., Borzilleri R., Gullo-Brown J., Fargnoli J., Fink B., Han W.C., Mortillo S., Vite G., Wautlet B., Wong T., Yu C., Zheng X., and Bhide R. J. Med. Chem. 47 (2004) 4054
10. Abdel-Rahman R.M. Pharmazie 56 (2001) 18
11. WHO, http://www.who.int/cancer/en/index.html.
12. Frohberg P., and Nuhn P. Heterocycles 43 (1996) 2549
13. Drutkowski G., Donner C., Schulze I., and Frohberg P. Tetrahedron 58 (2002) 5317
14. Molinspiration Cheminformatics, http://www.molinspiration.com, accessed on July 30, 2009.
15. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 23 (1997) 3
16. Frohberg P., Drutkowski G., and Wagner C. Eur. J. Org. Chem. 10 (2002) 1654
17. Frohberg P., Wagner C., Meier R., and Sippl W. Tetrahedron 62 (2006) 6050
18. Krauth F., Friedemann R., Rüttinger H.-H., and Frohberg P. ARKIVOC (2009) 150
19. Paschke A., Neitzel P.L., Walther W., and Schüürmann G. J. Chem. Eng. Data 49 (2004) 1639
20. OECD Guideline for Testing of Chemicals. 117 Partition Coefficients (n-octanol/water), HPLC Method, OECD, Paris, 1996.
21. OECD Guideline for Testing of Chemicals. 107 Partition Coefficients (n-octanol/water), Shake Flask Method, OECD, Paris, 1996.
22. Velpandian T., Mathur R., Agarwal N.K., Arora B., Kumar L., and Gupta S.K. J. Chromatogr., B 804 (2004) 431
23. Formariz T.P., Sarmento V.H.V., Silva-Junior A.A., Scarpa M.V., Santilli C.V., and Oliveira A.G. Colloids Surf., B: Biointerfaces 51 (2006) 54
24. Doležal R., Waisser K., Petrlíková E., Kuneš J., Kubicová L., Machácek M., Kaustová J., and Dahse H.-M. Arch. Pharm. Chem. Life Sci. 342 (2009) 113
25. Laube T., Bernet A., Dahse H.-M., Jacobsen I.D., and Seifert K. Bioorg. Med. Chem. 17 (2009) 1422
26. Dahse H.-M., Schlegel B., and Gräfe U. Pharmazie 56 (2001) 489
27. NCI, http://www.nci.nih.gov/cancertopics/types/leukemia.
28. Thorarensen A., Li J., Wakefield B.D., Romero D.L., Marotti K.R., Sweeney M.T., Zurenko G.E., and Sarver R.W. Bioorg. Med. Chem. Lett. 17 (2007) 3113
29. Zsila F., Fitos I., Bikádi Z., Simonyi M., Jackson H.L., and Lockwood S.F. Bioorg. Med. Chem. Lett. 14 (2004) 5357
30. Parikh H.H., McElwain K., Balasubramanian V., Leung W., Wong D., Morris M.E., and Ramanathan M. Pharm. Res. 17 (2000) 632
31. Epps D.E., Raub T.J., and Kezdy F.J. Anal. Biochem. 227 (1995) 342
32. Damrot J., Nübel T., Epe B., Roos W.P., Kaina B., and Fritz G. Br. J. Pharmacol. 149 (2006) 988